Supplements

Survodutide reduces body weight in Chinese adults with overweight or obesity

This phase 3 randomized controlled trial is designed to evaluate the efficacy, safety, and tolerability of survodutide (3.6 mg or 4.8 mg once weekly) versus placebo in Chinese adults with overweight or obesity. The primary endpoints are percentage change in body weight and achievement of ≥5% body weight reduction from baseline to week 52. Baseline characteristics show a mean BMI of 33.2 kg/m² and a high prevalence of obesity-related complications.

Last updated: Aug 20, 2026•1 RCTs•📖 Read as article →

Evidence Score

Evidence Score44/100
Human RCT★★☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN).

observational

Ji L, Chen L, Cheng Z, Lu Y, Yang Y, Fu F, Zhu Y, Jin L, Kloer IM · Diabetes therapy : research, treatment and education of diabetes and related disorders (2026)

Participants: N/A
Duration: 76 weeks
Intervention: Once-weekly subcutaneous survodutide (3.6 mg or 4.8 mg) plus lifestyle intervention
Outcome: Percentage change in body weight and achievement of ≥5% body weight reduction from baseline to week 52
Effect Size: N/A (results not yet reported)
Population: Chinese adults with overweight or obesity (BMI ≥28 kg/m² or BMI ≥24 kg/m² with at least one obesity-related complication)

Result:

PubMed: 42599381DOI: 10.1007/s13300-026-01908-x

Mechanism Graph

Survodutide is a dual agonist of GLP-1 and glucagon receptors
↓
It enhances insulin secretion and suppresses appetite
↓
It increases energy expenditure via glucagon receptor activation
↓
Result: Reduction in body weight

Limitations

  • ⚠Baseline characteristics only; no efficacy or safety results reported yet
  • ⚠Trial is ongoing; final outcomes not available
  • ⚠Specific to Chinese population; generalizability to other ethnicities may be limited

Frequently Asked Questions

What is survodutide?▼

Survodutide is a dual agonist of GLP-1 and glucagon receptors, being investigated for weight management.

What are the primary endpoints of the SYNCHRONIZE-CN trial?▼

The primary endpoints are the percentage change in body weight and the proportion of participants achieving ≥5% body weight reduction from baseline to week 52.

Who is eligible for this trial?▼

Chinese adults with BMI ≥28 kg/m² or BMI ≥24 kg/m² with at least one obesity-related complication.

What is the duration of the trial?▼

The trial lasts 76 weeks, with primary endpoints assessed at week 52.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Ji L, Chen L, Cheng Z, Lu Y, Yang Y, Fu F, Zhu Y, Jin L, Kloer IM. "Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN).." Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. PMID: 42599381 DOI: 10.1007/s13300-026-01908-x
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.